header logo image


Page 16«..10..15161718..3040..»

Archive for May, 2020

Neuropathic Pain Market to reach US$ 9,862.3 Million globally by 2027 Coherent Market Insights – GlobeNewswire

Monday, May 25th, 2020

SEATTLE, May 25, 2020 (GLOBE NEWSWIRE) -- Various lesions or diseases of the somatosensory system may lead to neuropathic pain. Nerve blockage and pharmacological remedies are used in the treatment and management of neuropathic pain.

The global neuropathic pain market is estimated to account for US$ 9,862.3 Mn in terms of value by the end of 2027.

Market Drivers:

High prevalence of cancer is expected to propel growth of the global neuropathic pain market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.

Market Opportunities:

R&D in neuropathic pain is expected to offer lucrative growth opportunities for players in the market. For instance, in May 2020, researchers from University Medical Center Hamburg-Eppendorf and other prominent universities in Germany reported that loss of C-fiber may lead to neuropathic pain in Schwannomatosis, a form of neurofibromatosis caused due to the occurrence of multiple schwannomas, tumors that develops from the Schwann cells.

Moreover, adoption of nanoparticles in therapies is also expected to aid in growth of the global neuropathic pain market. For instance, in May 2020, researchers from Chungnam National University Hospital, South Korea, reported that poly(D,L-lactic-co-glycolic acid)-encapsulated CX3CR1 small interfering RNAs nanoparticles may aid in the treatment of neuropathic pain.

Request for Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/3656

Key Takeaways:

The global neuropathic pain market was valued at US$ 6,313.4 Mn in 2019 and is forecast to reach US$ 9,862.3 Mn by 2027 at a CAGR of 5.6% between 2020 and 2027. Increasing prevalence of cancer is expected to propel growth of the global neuropathic pain market over the forecast period.

Anticonvulsants segment held dominant position in the global neuropathic pain market in 2019, accounting for 40.8% share in terms of value. Development of new drugs for the treatment of neuropathic pain is expected to drive the segment growth.

Diabetic neuropathy segment held dominant position in the global neuropathic pain market in 2019, accounting for 46.4% share in terms of value, followed by Chemotherapy-induced peripheral neuropathy and others, respectively. Increasing prevalence of diabetic neuropathy in developing economies is expected to assist the growth of the segment during the forecast period.

Market Trends:

Various studies are focused on developing alternatives to drugs in the treatment of neuropathic pain. For instance, in March 2020, researchers at the Autonomous University of the State of Hidalgo, Mexico, reported that pomegranate and secondary metabolites can be effective in the treatment of inflammatory, nociceptive, and neuropathic pain.

The market is witnessing adoption of combination therapies as an effective approach in the treatment of neuropathic pain. For instance, in March 2020, researchers from Universitat Autnoma de Barcelona, Spain, reported that NeuroHeal a combination of two repurposed drugs: Acamprosate and Ribavirin reduces the appearance of neuropathic pain in peripheral nerve injury.

Competitive Landscape:

Major players operating in the global neuropathic pain market include, Pfizer, Inc., Johnson & Johnson Services, Inc., Sanofi S.A., CODA Biotherapeutics, Inc., Eliy Lily and Company, GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Sqibb, Baxter Healthcare Corporation, Neuroheal Biomedicals, S.L., and Depomed, Inc.

Key Developments:

Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in May 2020, CODA Biotherapeutics, Inc. collaborated with the Facial Pain Research Foundation for R&D of new therapies for trigeminal neuralgia and related neuropathic pain using CODAs chemogenetic gene therapy platform.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3656

Taxonomy (Scope, segments)

See more here:
Neuropathic Pain Market to reach US$ 9,862.3 Million globally by 2027 Coherent Market Insights - GlobeNewswire

Read More...

World Neuropathy Pain Treatment Market Analysis 2020, Featuring Key Players Assertio Therapeutics Inc., Endo International Plc and Pfizer -…

Monday, May 25th, 2020

DUBLIN--(BUSINESS WIRE)--The "Global Neuropathy Pain Treatment Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

The neuropathy pain treatment market is poised to grow by $ 1702.89 mn during 2020-2024 progressing at a CAGR of 5% during the forecast period. The report on the neuropathy pain treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The market is driven by the presence of large patient pool and focus toward the development of novel therapeutics for postherpetic neuralgia.This study identifies the growing focus on the development of drugs for the treatment of diabetic neuropathy pain as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years.

The neuropathy pain treatment market analysis includes type segment and geographic landscape.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. The neuropathy pain treatment market covers the following areas:

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neuropathy pain treatment market vendors that include Abbott Laboratories, Assertio Therapeutics Inc. , AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi. Also, the neuropathy pain treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.

This market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Indication

Market Segmentation by drug class

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/4n7ghp

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

More here:
World Neuropathy Pain Treatment Market Analysis 2020, Featuring Key Players Assertio Therapeutics Inc., Endo International Plc and Pfizer -...

Read More...

Novaremed Announces IND Submitted to U.S. FDA for Phase 2 Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy; Also…

Monday, May 25th, 2020

BASEL, Switzerland--(BUSINESS WIRE)--Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the novel drug candidate (NRD135S.E1) for the treatment of Painful Diabetic Peripheral Neuropathy (PDPN) to evaluate NRD135S.E1 in a Phase 2 study.

Novaremed had received initial feedback from the FDA during a Pre-IND meeting held on July 24, 2019. The Phase 2 study, designed as a randomized, double-blind, placebo-controlled study, will enroll patients experiencing neuropathic pain caused by Diabetes Mellitus. Eligible patients will be randomized to receive oral doses of either NRD135S.E1 or placebo once daily for 3 months.

Submitting this IND is an important next step in the clinical development of NRD135S.E1 for the treatment of PDPN and we are moving rapidly to potentially address a global unmet medical need, said Sara Mangialaio, M.D., Ph.D., CMO and Head of R&D at Novaremed. We look forward to launching this Phase 2 study as soon as possible. This study will provide further important information about the safety and efficacy of NRD135S.E1, which was very well tolerated and induced a clinically relevant reduction in pain in the previous Phase 2 Proof of Concept study of 3-week duration.

The company is currently in discussions with potential investors to raise the necessary funding to support the conduct of the proposed Phase 2 study, as well as prepare for further late-stage development activities of NRD135S.E1.

Safe and effective therapies are critical to provide patients and physicians with treatment alternatives for PDPN, said Subhasis Roy, M.Com, MBA, CEO/COO of Novaremed. The next steps announced today for NRD135S.E1 highlight the result of Novaremeds many years of pursuit to move a novel non-opioid drug against PDPN as rapidly as possible.

Novaremed also announced today the appointment of three new members to the companys board of directors, effective May 14, 2020. Joining the board are Thomas Meier, Ph.D., Benyamin Sidon and Eliahu Kaplan, M.D. These appointments bring Novaremeds total board membership to six.

Dr. Thomas Meier is a dynamic life sciences entrepreneur who established Santhera Pharmaceuticals (SIX Exchange: SANN) as a successful Biotech/Specialty Pharma company in Switzerland. In the past 20 years he held executive positions (CSO and CEO) and successfully supported or executed mergers, acquisitions, product licensing and turn-around situations. Since 2017 he is member of Santheras Board of Directors. He holds a Ph.D. in Biology from the University of Basel and carried out post-doctoral training at the University of Colorado Health Sciences Center (USA) and Biozentrum, University of Basel, where he became group leader and lecturer in neurosciences before joining the industry. He is an internationally recognized scientist with track record in clinical research of orphan diseases (neuromuscular, neuro-ophthalmology). In 2007, he received the BioValley Basel Award for his outstanding contributions to the life sciences in the area.

Mr. Benyanin Sidon is an Investment Advisor at Gefen Biomed Investments, an Israeli public company, investing in Israeli startups with disruptive technologies. He has been active in fund raising and portfolio management activities in Israel over the last three decades. He sits on the board of directors of several portfolio companies of Gefen in Israel and abroad. He has a B.A. in Economics from Tel Aviv University, Israel.

Dr. Eliahu Kaplan is the founder, former board member and CEO of Novaremed Ltd as well as former CEO and Chief Innovator of Novaremed AG. He has more than 30 years of experience in the pharmaceutical industry particularly in oncology drug development. He worked at Farmitalia Carlo Erba in Milan, Italy as Director of Oncology Corporate Medical Department, as Medical Director in Freiburg, Germany as well as in Israel. In addition, between 1994 and 1998, he founded Seneb-Pharma, a consulting firm to consult in the field of R&D of drugs and medical products. Between 2005 and 2006 he was Medical Director (part-time) at Oridion BreathID in Israel.

We are excited to welcome Thomas, Benny and Eli to our board of directors. They bring decades of leadership in drug development and in business, that are vital to our future operations and strategy, said Isaac Kobrin, M.D., Chairman of the Board of Novaremed.

Notes to the Editor:

About Novaremed

Novaremed Ltd, a wholly owned subsidiary of Novaremed AG was founded in 2008 in Israel and Novaremed AG was founded in 2017 in Switzerland. Novaremed Ltd is developing NRD135S.E1, an orally active non-opioid small molecule with a novel mechanism of action against PDPN. In a Phase 2 Proof of Concept study, NRD135S.E1 showed clinically relevant reduction in patient-reported pain and an excellent safety and tolerability profile. Novaremed Ltd is currently preparing to conduct a Phase 2 study in PDPN. For more information, visit http://www.novaremed.com.

See the original post here:
Novaremed Announces IND Submitted to U.S. FDA for Phase 2 Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy; Also...

Read More...

How Do You Deal With The Painful Tingling of Neuropathy? A Side Effect of Chemotherapy for Ovarian Cancer – SurvivorNet

Monday, May 25th, 2020

A Lesser-Known Chemotherapy Side Effect

The well-known side effects of chemotherapy can usually be dealt with fairly effectively for many women, though we empathize with anyone having to go through chemo. Two of the most common chemo side effects, nausea and hair loss, can both be managed with available treatments. The same is true of another, lesser-known side effect of chemotherapy, called neuropathy.

Neuropathy is the medical term for numbness or tingling in the fingers or toes, caused by powerful chemotherapy drugs damaging the peripheral nerves. Women receiving ovarian cancer chemotherapy with the taxane (Taxol) or platinum group of drugs are particularly susceptible to this side effect of treatment.

Fortunately oncologists are usually well-versed in this side effect, and take steps to try and minimize the problem during treatment. We usually assess for the degree of neuropathy prior to every dose of chemotherapy, says Dr. Manojkumar Bupathi, a medical oncologist at Rocky Mountain Cancer Center in Littleton, Colorado. In the event that neuropathy is getting worse, we can adjust the doses or delay treatments. We can also switch a patients drugs if it becomes an ongoing issue.

Symptoms

In addition to the numbness and tingling sensations that are characteristic of neuropathy, some patients may also experience:

Treatment

Patients can try several different approaches to dealing with neuropathy. We usually ask patients to use things like ice packs or protective gloves to try and mitigate the neuropathy, says Dr. Bupathi.

When simple treatments like this dont work, patients may want to consult a neurologist who can help treat the condition with a variety of different medications, including:

Prognosis

Most neuropathy goes away and improves over time, but sometimes it can take upwards of a year before it gets better, says Dr. Bupathi. While neuropathy may be permanent, Dr. Bupathi says that it usually persists as numbness or tingling, and isnt usually debilitating, where someone isnt able to walk or do basic things like buttoning a shirt or lifting a pen off a countertop.

If youre undergoing chemotherapy and start to experience symptomsnumbness, tingling, pain or weakness in the hands and feetmake sure to let your oncologist know so that you can take steps to relieve the symptoms and prevent permanent nerve damage.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Manojkumar Bupathi is a medical oncologist with Rocky Mountain Cancer Centers. Read More

Neuropathy is the medical term for numbness or tingling in the fingers or toes, caused by powerful chemotherapy drugs damaging the peripheral nerves. Women receiving ovarian cancer chemotherapy with the taxane (Taxol) or platinum group of drugs are particularly susceptible to this side effect of treatment.

Symptoms

In addition to the numbness and tingling sensations that are characteristic of neuropathy, some patients may also experience:

Treatment

Patients can try several different approaches to dealing with neuropathy. We usually ask patients to use things like ice packs or protective gloves to try and mitigate the neuropathy, says Dr. Bupathi.

When simple treatments like this dont work, patients may want to consult a neurologist who can help treat the condition with a variety of different medications, including:

Prognosis

Most neuropathy goes away and improves over time, but sometimes it can take upwards of a year before it gets better, says Dr. Bupathi. While neuropathy may be permanent, Dr. Bupathi says that it usually persists as numbness or tingling, and isnt usually debilitating, where someone isnt able to walk or do basic things like buttoning a shirt or lifting a pen off a countertop.

If youre undergoing chemotherapy and start to experience symptomsnumbness, tingling, pain or weakness in the hands and feetmake sure to let your oncologist know so that you can take steps to relieve the symptoms and prevent permanent nerve damage.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Manojkumar Bupathi is a medical oncologist with Rocky Mountain Cancer Centers. Read More

Originally posted here:
How Do You Deal With The Painful Tingling of Neuropathy? A Side Effect of Chemotherapy for Ovarian Cancer - SurvivorNet

Read More...

Chemotherapy Induced Peripheral Neuropathy Treatment Industry Growth Analysis 2020-2026 with Market Share, Size, Trends, Revenue, CAGR and SWOT…

Monday, May 25th, 2020

This report studies the Chemotherapy Induced Peripheral Neuropathy Treatment Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Chemotherapy Induced Peripheral Neuropathy Treatment Market analysis segmented by companies, region, type and applications in the report.

Market Segment by Companies: Aptinyx, Asahi Kasei Pharma, Regenacy Pharmaceuticals, MAKScientific, Metys Pharmaceuticals, Nemus Bioscience, PledPharma, Sova Pharmaceuticals, DermaXon, Immune Pharmaceuticals, Kineta, Krenitsky Pharmaceuticals, PeriphaGen, Apexian Pharma, WinSanTor, Solasia Pharma, and more

Request a Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-professional-survey-2019-by-manufacturers-regions-countries-types-and-applications-forecast-to-2024?utm_source=coleofduty&utm_medium=39

Chemotherapy Induced Peripheral Neuropathy Treatment Market continues to evolve and expand in terms of the number of companies, products, and applications that illustrates the growth perspectives. The report also covers the list of Product range and Applications with SWOT analysis, CAGR value, further adding the essential business analytics. Chemotherapy Induced Peripheral Neuropathy Treatment Market research analysis identifies the latest trends and primary factors responsible for market growth enabling the Organizations to flourish with much exposure to the markets.

Market Segment by Regions, regional analysis covers:

Research Objectives:

Browse More Details @ https://www.reportsandmarkets.com/reports/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-professional-survey-2019-by-manufacturers-regions-countries-types-and-applications-forecast-to-2024?utm_source=coleofduty&utm_medium=39

The Chemotherapy Induced Peripheral Neuropathy Treatment Market research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Table of Contents:

Key questions answered in this report:

Get Complete Report @ https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=3323528&utm_source=coleofduty&utm_medium=39

About Us:

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serves our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Continue reading here:
Chemotherapy Induced Peripheral Neuropathy Treatment Industry Growth Analysis 2020-2026 with Market Share, Size, Trends, Revenue, CAGR and SWOT...

Read More...

COVID-19 impact: Chemotherapy Induced Peripheral Neuropathy Treatment Market : In-depth Study on Industry Size and Analysis on Emerging Growth Factors…

Monday, May 25th, 2020

The report on the Chemotherapy Induced Peripheral Neuropathy Treatment market provides a birds eye view of the current proceeding within the Chemotherapy Induced Peripheral Neuropathy Treatment market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Chemotherapy Induced Peripheral Neuropathy Treatment market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Chemotherapy Induced Peripheral Neuropathy Treatment market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Chemotherapy Induced Peripheral Neuropathy Treatment market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Chemotherapy Induced Peripheral Neuropathy Treatment market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2638040&source=atm

The major players profiled in this Chemotherapy Induced Peripheral Neuropathy Treatment market report include:

Segment by Type, the Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented intoCalcium Channel 2-delta LigandsAntidepressantsOpioidsOthers

Segment by Application, the Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented intoPlatinum AgentsTaxanesVinca AlkaloidsOthers

Regional and Country-level AnalysisThe Chemotherapy Induced Peripheral Neuropathy Treatment market is analysed and market size information is provided by regions (countries).The key regions covered in the Chemotherapy Induced Peripheral Neuropathy Treatment market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.Competitive Landscape and Chemotherapy Induced Peripheral Neuropathy Treatment Market Share AnalysisChemotherapy Induced Peripheral Neuropathy Treatment market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Chemotherapy Induced Peripheral Neuropathy Treatment business, the date to enter into the Chemotherapy Induced Peripheral Neuropathy Treatment market, Chemotherapy Induced Peripheral Neuropathy Treatment product introduction, recent developments, etc.The major vendors covered:Aptinyx IncAsahi Kasei Pharma CorpRegenacy PharmaceuticalsMAKScientific LLCMetys Pharmaceuticals AGNemus Bioscience IncPledPharmaSova Pharmaceuticals IncDermaXon LLCKineta IncKrenitsky Pharmaceuticals IncPeriphaGenApexian PharmaWinSanTorSolasia Pharma K.K.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2638040&licType=S&source=atm

Key Market Related Questions Addressed in the Report:

Important Information that can be extracted from the Report:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2638040&source=atm

Read the original:
COVID-19 impact: Chemotherapy Induced Peripheral Neuropathy Treatment Market : In-depth Study on Industry Size and Analysis on Emerging Growth Factors...

Read More...

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 Company Profiles, Key Strategic Moves and Developments, Operating Business…

Monday, May 25th, 2020

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026 aims to target the major concepts related to market growth, major types, and various end users applicable, regional analysis, productivity structure, current market situation. The market report is a proficient and deep analysis of the present situation and challenges. The report offers analysis with regards to the past and current market situation of the global Chemotherapy Induced Peripheral Neuropathy Treatment market. The report highlights all introducing income segmentation and also a firm sketch of the top players. It comprises streamlined financial data obtained from various research sources. The report analyzes the market players, sub-segments and sections, product category, and major improvements in the market.

Overview of The Report:

Top players are examined for revenue areas manufacturing, market rivalry, capacity, sales (value), moderate price, fabricating base supply and market share, and product types. The report also computes the limits and strong points of the players. The report studies key opportunities in the market and segmentation of market size, by volume and value, on the basis of application type and geography. The report focuses on innovative trends, implementing reasonable pricing stats in the competitive market. The overall description of the global Chemotherapy Induced Peripheral Neuropathy Treatment market will assist our viewers to comprehend the market in the best way. It sheds light on the industry parameters by accessing the market growth, consumption volume, the upcoming market trends, and the different prices variation for the forecast year from 2020 to 2026.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/41488

The report covers a number of the players in the market, including: Aptinyx, Asahi Kasei Pharma, Regenacy Pharmaceuticals, MAKScientific, Metys Pharmaceuticals, Nemus Bioscience, PledPharma, Sova Pharmaceuticals, DermaXon, Immune Pharmaceuticals, Kineta, Krenitsky Pharmaceuticals, PeriphaGen, Apexian Pharma, WinSanTor, Solasia Pharma,

Segmentation by product type and analysis of the market: Calcium Channel _2-delta Ligands, Antidepressants, Opioids, Others

Segmentation by application and analysis of the market: Platinum Agents, Taxanes, Vinca Alkaloids, Others

The scope of the report covers market eventualities to a comparative rating between major players, price, and profit of the required market regions. This report covers North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). It focuses on the foremost and the progressing countries from every region in detail.

The report represents the ongoing marketing trends that are faced by the market competitors, the ups, and downs in the global Chemotherapy Induced Peripheral Neuropathy Treatment market. Subsequently, it discovers the worlds main Chemotherapy Induced Peripheral Neuropathy Treatment industry market requirements, for example, demand, distribution, profit, production, capacity, and promote growth speed and prediction, etc. The company further divides even the economy, by state also from application/type for its landscape analysis.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/41488/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2026

Major Points From TOC:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

More here:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 Company Profiles, Key Strategic Moves and Developments, Operating Business...

Read More...

Ischemic Optic Neuropathy Treatment Market Upcoming Trends, Incredible Possibilities, Business Opportunities ,Regional Outlook and Forecast 2018-2026…

Monday, May 25th, 2020

New York City, United States The change during the COVID-19 pandemic has overhauled our dependence on pattern setting developments, for instance, expanded reality, computer generated reality, and the Healthcare web of things. The unfulfilled cash related targets are persuading the relationship to grasp robotization and forefront advancements to stay ahead in the market competition. Associations are utilizing this open entryway by recognizing step by step operational needs and showing robotization in it to make an automated structure as far as might be feasible

Ischemic optic neuropathy is caused due to a small vessel infraction of the optic nerve and is a major cause of blindness or impaired vision among the inflicted. There are two types of ischemic optic neuropathies viz. anterior ischemic optic neuropathy and posterior or non-anterior ischemic optic neuropathy. Anterior ischemic optic neuropathy is caused by the inflammation of arteries supplying blood to the optic nerve whereas posterior or non-anterior ischemic optic neuropathy is caused due to reasons other than inflammation of the arteries. Anterior ischemic optic neuropathy is more prevalent as compared to posterior ischemic optic neuropathy. In anterior ischemic optic neuropathy, immediate treatment is required to prevent vision loss in the fellow eye as approximately 50 percent of cases have chances of blindness in another eye within a span of 5 to 10 days without treatment. The symptoms of ischemic optic neuropathy include unilateral, acute and painless visual loss for hours to days. Hypertension, diabetes, and hypercholesterolemia are some of the well-known risk factors associated with ischemic optic neuropathy disease. Other factors include generalized hypoperfusion, sleep apnea, nocturnal hypotension, vasospasm, severe anemia and failure of autoregulation.

Technological advancements in ischemic optic neuropathy treatment and availability of alternative drugs are anticipated boost the demand for ischemic optic neuropathy treatments over the forecast period.

Request to Sample report @https://www.persistencemarketresearch.com/samples/23077

The global ischemic optic neuropathy treatment market can be segmented on the basis of disease type, treatment type and end user.

On the basis of disease type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of treatment type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of end user, the global ischemic optic neuropathy treatment market can be segmented into:

The global ischemic optic neuropathy treatment market is expected to register a significant CAGR over the forecast period. The increasing adoption of recently approved intravitreal implants in the treatment of ophthalmology diseases is anticipated to propel the growth of the ischemic optic neuropathy treatment market over the forecast period. Leading pharmaceutical and drug manufacturing companies from developed countries are substantially investing in R&D, infrastructure and new technologies in ophthalmology therapeutics to capture a market share in the growing burden of eye diseases, which also boosts the growth of the global ischemic optic neuropathy treatment market. With growing awareness towards eye-related complications that lead to blindness, geriatric population and diabetic patients in developed countries, such as the U.S., Russia, and Poland, Germany and Japan are seen to have a proactive approach for treatment related to complications rather than reactive treatment, which also bolsters the growth of the market of ischemic optic neuropathy treatment.

Corticosteroid is the first choice of therapy for patients with ischemic optic neuropathy in prominent countries, such as the U.S., Germany, France, and Russia; however, a majority of patients have developed resistance to anti-VEGF, which leads to the adoption of alternative therapy in patients with ischemic optic neuropathy. This is anticipated to drive the growth of the global ischemic optic neuropathy treatment market in the long run.

Request For TOC @https://www.persistencemarketresearch.com/toc/23077

However, medications such as intravitreal injections of anti-VEGF drugs and corticosteroids lead to an instant increase in intraocular pressure, which may lead to severe adverse effects such as conjunctival haemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased and vitreous detachment. This may restrain the growth of the global ischemic optic neuropathy treatment market.

Regional analysis includes

North America is a dominant region in the market and contributes a leading share to the global ischemic optic neuropathy treatment market in terms of revenue. The market in the region is expected to register significant growth over the forecast period due to the availability of developed medical infrastructure and treatment facilities in the region. Europe also contributes a moderate share and registered a healthy growth rate in the global ischemic optic neuropathy treatment market. The APEJ region has become a lucrative market for ischemic optic neuropathy treatment and is anticipated to register a significant share over the forecast period, due to the increase in research and development activities along with the growth in medical tourism in the region. Latin America and MEA are in the nascent stage in the global ischemic optic neuropathy treatment market and are expected to register moderate growth over the forecast period.

For in-depth competitive analysis, buy[emailprotected]https://www.persistencemarketresearch.com/checkout/23077

Some of the market players operating in the ischemic optic neuropathy treatment market include ,

The report covers exhaustive analysis on:

Read the original here:
Ischemic Optic Neuropathy Treatment Market Upcoming Trends, Incredible Possibilities, Business Opportunities ,Regional Outlook and Forecast 2018-2026...

Read More...

The possible link between genetics and coronavirus – CBS19.tv KYTX

Monday, May 25th, 2020

SAN ANTONIO Scientists around the world are racing to understand coronavirus and why most people who are infected show mild to moderate symptoms or sometimes no symptoms at all and others develop a severe form of the disease, in some cases resulting in death.

23andMe has provided personalized genetic reports for years. But now he biotechnology company is switching gears to help battle coronavirus with a new study, and they're looking for those with a positive diagnosis to take part.

"Given that COVID-19 has taken a turn of turning our lives upside down so very, very quickly, at this stage we just don't know to what extent genetics plays a role in determining the severity of outcomes," said Adam Auton, the principal scientist of statistical genetics at 23andMe.

To participate in the study, you must be over 18 years of age and live in the U.S., be willing to provide a saliva sample for DNA testing, complete an online survey, have a positive coronavirus diagnosis, and you must have been hospitalized due to coronavirus-related symptoms. The stronger your symptoms, the likelier you could play a big part in the research.

"In order to maximize our abilities to make a discovery, we would really like to provide people with severe outcomes (the opportunity) to come into the study and participate in the study," Auton said.

This study could even shed some light on a phenomenon known as the COVID cliff when patients who seem to be improving suddenly get worse and whether or not genetics play a role. Dr. Diego Maselli, the Medical Director of respiratory therapy at University Hospital told us,

"Unfortunately, some of these patients, when this happens or this phenomenon starts to happen, then they get sicker and they end up in the ICU and sometimes on a ventilator," said Diego Maselli, the medical director of respiratory therapy at University Hospital.

"The hope (is) that our study can help provide information that will provide some answers to those sorts of questions," Auton said.

So far, 600,000 Americans have agreed to participate, but only 9,000 say they had COVID-19. 23andMe is looking for thousands more.

"It's the nature of genetic studies that we really need very large numbers of people to participate," Auton said.

If you would like more information about the study or to participate, click here.

RELATED: Large-scale coronavirus vaccine testing program aims to meet year-end goal, report

RELATED: Local leaders working to ensure that city's homeless population doesn't explode when eviction cases resume in June

RELATED: Matthew McConaughey delivering masks to rural hospitals in Texas during COVID-19 pandemic

Read the rest here:
The possible link between genetics and coronavirus - CBS19.tv KYTX

Read More...

What’s on TV Tuesday: ‘The Genetic Detective’; coronavirus – Los Angeles Times

Monday, May 25th, 2020

During the coronavirus crisis, the Los Angeles Times is making some temporary changes to our print sections. The prime-time TV grid is on hiatus in print but an expanded version is available in your daily Times eNewspaper. You can also find a printable PDF online: latimes.com/whats-on-tv.

Americas Got Talent Simon Cowell, Heidi Klum, Howie Mandel and host Terry Crews return with new judge Sofia Vergara in the season premiere of the unscripted competition. 8 p.m. NBC

DCs Stargirl After Courtney (Brec Bassinger) has an unexpected run-in with a member of the Injustice Society of America, Pat (Luke Wilson) reveals the truth to her about their history in a new episode of this superhero series. 8 p.m. CW

Deadliest Catch In this new episode Junior makes the risky decision to venture into Russian waters in his quest for golden crab, while cocaptains Jake and Johnathan try to broker an alliance with longtime rival Keith Colburn. 8 p.m. Discovery

DCs Legends of Tomorrow The Legends are scattered into different TV shows in this new episode. 9 p.m. CW

Chopped The competing chefs get a pork theme in this new episode of the culinary competition. 9 p.m. Food Network

Grant As the Civil War continues, Ulysses S. Grant takes incredible risks and becomes Abraham Lincolns favorite general. 9 p.m. History

World of Dance Contestants must perform in a stripped-down warehouse to prove they have what it takes for this unscripted competition series. Jennifer Lopez, Derek Hough and Ne-Yo are the judges. (N) 10 p.m. NBC

The Genetic Detective Investigative genetic genealogist CeCe Mooreworks with the Seattle areas Snohomish County Sheriffs Office on a double homicide from 1987 in the premiere of this documentary series. (N) 10 p.m. ABC

Supermarket Stakeout Four chefs are handing out cash to shoppers in Glendale as they compete to make the best barbecue dish in this new episode. 10 p.m. Food Network

REAL Sports With Bryant Gumbel This new episode is a virtual roundtable discussion with professional players association officials DeMaurice Smith (NFL), Michele Roberts (NBA) and Tony Clark (MLB) to discuss the impact of the COVID-19 pandemic on their games and the restart of professional sports in America. 10 p.m. HBO

Kingdom of the Mummies A team of archaeologists led by Ramadan Hussein makes the discovery of a lifetime. (N) 10:03 p.m. National Geographic

Space X: Journey To the Future (N) 10 p.m. Discovery

Coronavirus Pandemic (N) 8 and 9 a.m. CNN

Coronavirus Update (N) Noon CW

Pandemic: What You Need to Know Noon ABC

Coronavirus Crisis (N) 7 p.m. Fox

CBS This Morning Sen. Joni Ernst (R-Iowa). (N) 7 a.m. KCBS

Today (N) 7 a.m. KNBC

KTLA Morning News (N) 7 a.m. KTLA

Good Morning America Tracee Ellis Ross; Adam Rippon; Tory Johnson. (N) 7 a.m. KABC

Good Day L.A. (N) 7 a.m. KTTV

Live With Kelly and Ryan Keegan-Michael Key (Game On!); Madison Beer performs. (N) 9 a.m. KABC

The View (N) 10 a.m. KABC

Rachael Ray Clinton Kelly. (N) 10 a.m. KTTV

The Talk (N) 1 p.m. KCBS

Tamron Hall Janelle Mone (Homecoming); dancer Misty Copeland, Swans for a Relief. (N) 1 p.m. KABC

The Real Guest host Eva Marcille. (N) 1 p.m. KTTV

The Kelly Clarkson Show Joel McHale; Grace Byers; Duff Goldman cake demo. (N) 2 p.m. KNBC

The Ellen DeGeneres Show Howie Mandel; Sarah Cooper. (N) 3 p.m. KNBC

Amanpour and Company (N) 11 p.m. KCET; midnight KVCR; 1 a.m. KLCS

The Tonight Show Starring Jimmy Fallon Jennifer Lopez; Michelle Obama; Brad Pitt. (N) 11:34 p.m. KNBC

The Late Show With Stephen Colbert Andrew Cuomo; Christine and the Queens perform. 11:35 p.m. KCBS

Jimmy Kimmel Live! (N) 11:35 p.m. KABC

Nightline (N) 12:06 a.m. KABC

Cry Freedom (1987) 8:48 a.m. Encore

Dont Think Twice (2016) 8:59 a.m. Starz

A Bronx Tale (1993) 9 a.m. AMC

Total Recall (1990) 9 a.m. IFC

I Know Where Im Going! (1945) 9:15 a.m. TCM

Chocolat (2000) 9:35 a.m. HBO

While You Were Sleeping (1995) 10 a.m. Showtime

The Birds (1963) 10 a.m. Sundance

Black Hawk Down (2001) 10:33 a.m. Starz

The Game (1997) 11:29 a.m. Encore

Fury (2014) 11:30 a.m. AMC

Ice Age (2002) 11:30 a.m. Freeform

Jaws (1975) 11:40 a.m. HBO

Overlord (2018) 1:25 p.m. Epix

Hook (1991) 1:30 p.m. Freeform

Far and Away (1992) 1:40 p.m. Cinemax

Undercover Brother (2002) 1:59 p.m. Starz

American Sniper (2014) 2:30 p.m. AMC

Harry Potter and the Deathly Hallows: Part 1 (2010) 2:50 p.m. Syfy

Travels With My Aunt (1972) 3 p.m. TCM

The Cider House Rules (1999) 3:27 p.m. Starz

8 Mile (2002) 3:30 p.m. VH1

Unstoppable (2010) 4 p.m. HBO

The Negotiator (1998) 4 p.m. Ovation

Men of Honor (2000) 4 and 6:30 p.m. WGN America

Despicable Me (2010) 4:40 p.m. Freeform

Crawl (2019) 4:55 p.m. Epix

Incendiary Blonde (1945) 5 p.m. TCM

Wonder Woman (2017) 5 p.m. TNT

Top Gun (1986) 5:30 p.m. AMC

The Meddler (2015) 5:34 p.m. Starz

First Man (2018) 5:35 p.m. Cinemax

Harry Potter and the Deathly Hallows: Part 2 (2011) 6:05 p.m. Syfy

Despicable Me 2 (2013) 6:45 p.m. Freeform

Lady Sings the Blues (1972) 7:15 p.m. TCM

Drag Me to Hell (2009) 7:19 p.m. Encore

John Wick: Chapter 3 Parabellum (2019) 7:45 p.m. HBO

Ghost (1990) 8 and 11 p.m. BBC America

The Cabin in the Woods (2011) 8 p.m. Epix

The Hangover (2009) 8 p.m. IFC

Shrek (2001) 8:55 p.m. Freeform

The Usual Suspects (1995) 9 p.m. Ovation

Funny Girl (1968) 10 p.m. TCM

Star Trek (2009) 11:05 p.m. AMC

The Descent (2005) 11:05 p.m. Epix

The Professional (1994) 11:30 p.m. Ovation

More:
What's on TV Tuesday: 'The Genetic Detective'; coronavirus - Los Angeles Times

Read More...

Gene for "Thinness" Identified that May Help to Resist Weight Gain – Genetic Engineering & Biotechnology News

Monday, May 25th, 2020

An international research team has identified a candidate thinness gene that could help to explain why some people can seemingly stay slim no matter what they eat. A genetic association study that analyzed data from more than 47,000 people in an Estonian biobank implicated ALK as a key gene that may regulate thinness and play a role in resisting weight gain in metabolically healthy thin people. Further studies in animal models showed that deleting ALK resulted in thinner flies and thinner mice, and demonstrated that ALK expression in the brain may be involved in regulating energy expenditure.

ALK is already a recognized anticancer target, and the researchers suggest that targeting the gene may represent a future therapeutic strategy against obesity. If you think about it, its realistic that we could shut down ALK and reduce ALK function to see if we did stay skinny, said Josef Penninger, PhD, director of the Life Sciences Institute and professor of the department of medical genetics at the University of British Columbia. ALK inhibitors are used in cancer treatments already. Its targetable. We could possibly inhibit ALK, and we actually will try to do this in the future. Penninger is senior author of the teams published paper in Cell, which is titled, Identification of ALK in Thinness. The reported studies involved a multidisciplinary team of researchers in Austria, Switzerland, Estonia, China, Australia, Canada, and Sweden, and the U.S.

Theres considerable variability in how susceptible different people are to putting on weight. We all know these people: its around one percent of the population, said Penninger. They can eat whatever they want and be metabolically healthy. They eat a lot, they dont do squats all the time, but they just dont gain weight.

Body mass index (BMI), which is commonly used to classify weight categories, is a highly complex trait that is impacted by genes and environmental cues, the researchers wrote. And while more than 700 common single nucleotide polymorphisms (SNPs) have been linked with BMI, only a limited number of genes involved in regulating human body weight have been identified and validated. To date, most studies have focused on susceptibility to obesity, and only a few have looked at the genetic basis of thinness in humans or animal models. Everybody studies obesity and the genetics of obesity, Penninger pointed out. We thought, Lets just turn it around and start a new research field. Lets study thinness.

To do this Penningers team analyzed data from the Estonian Biobank, which includes 47,102 people aged 2044 years. The investigators carried out a genome-wide association study (GWAS) to compare the DNA samples and clinical data of healthy thin individualswho were in the lowest 6th percentilewith normal-weight individuals, in the search for genetic variants linked with thinness. Their results highlighted genetic variants in the ALK gene that were specific to the thin individuals.

Scientists have known that the ALK gene frequently mutates in various types of cancer, and while it is viewed as an oncogene that can drive the development of tumors, the role of ALK outside of cancer isnt understood. ALK has been extensively studied in cancer, but little is known about the biological role of ALK outside the context of cancer, they wrote. The new finding suggested that the ALK gene might play a role as a thinness gene involved in weight-gain resistance.

The researchers investigated the association between ALK and thinness through a series of studies in Drosophila fruit flies, and in mice. Their experiments demonstrated that mice in which the ALK gene was knocked out remained thin and were resistant to diet-induced obesity. Intriguingly, Alk knockout mice were significantly protected against HFD-induced obesity, the researchers wrote. ALK deficiency was also linked with reduced weight gain in a genetic obesity mouse model. Even when the ALK knockout mice had the same diet and activity levels as normal mice, they still demonstrated lower body weight and body fat from an early age, which persisted into adulthood.

Further studies in mice suggested that ALK, which is highly expressed in the brain, plays a role in instructing the fat tissues to burn more fat from food. Expression analysis revealed high Alk mRNA levels in the hypothalamus, especially in the PVN, which is also true for humans, the investigators wrote. Mechanistically, we found that ALK expression in hypothalamic neurons controls energy expenditure via sympathetic control of adipose tissue lipolysis Our genetic and mechanistic experiments identify ALK as a thinness gene, which is involved in the resistance to weight gain.

The findings could help scientists develop therapeutics against ALK as a future strategy against obesity. The team also plans to further study how neurons that express ALK regulate the brain at a molecular level to balance metabolism and promote thinness.

The Estonian Biobank that the team studied was ideal because of its wide age range and its strong phenotype data. We took advantage of the wide age range of the unique Estonian biobank recruitment as well as its strong phenotypic datasets, making ECGUT [Estonian Genome Center of the University of Tartu] an ideal starting point to identify potential variants and genes playing a role in thinness, the scientists noted. Even so, one limitation for replicating these findings is that biobanks that collect biological or medical data and tissue samples dont have a universal standard in data collection, which makes comparability a challenge. The researchers say they will need to confirm their findings with other data banks through meta-analyses. You learn a lot from biobanks, said Penninger. But, like everything, its not the ultimate answer to life, but theyre the starting points and very good points for confirmation, very important links and associations to human health.

The team suggests its work is unique in its combination of populationand genome-wide-scale analyses into the genetic basis of thinness, with in vivo analyses of gene function in mice and flies. Its great to bring together different groups, from nutrition to biobanking, to hardcore mouse and fly genetics, stated Penninger. Together, this is one story including evolutionary trees in metabolism, the evolutionary role of ALK, human evidence, and hardcore biochemistry and genetics to provide causal evidence.

Continue reading here:
Gene for "Thinness" Identified that May Help to Resist Weight Gain - Genetic Engineering & Biotechnology News

Read More...

Is Applied Genetic Technologies (AGTC) Outperforming Other Medical Stocks This Year? – Yahoo Finance

Monday, May 25th, 2020

Investors focused on the Medical space have likely heard of Applied Genetic Technologies (AGTC), but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Applied Genetic Technologies is one of 889 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AGTC is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past three months, the Zacks Consensus Estimate for AGTC's full-year earnings has moved 11.64% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

According to our latest data, AGTC has moved about 1.77% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -1.66% on a year-to-date basis. This means that Applied Genetic Technologies is outperforming the sector as a whole this year.

To break things down more, AGTC belongs to the Medical - Biomedical and Genetics industry, a group that includes 382 individual companies and currently sits at #16 in the Zacks Industry Rank. On average, this group has gained an average of 8.25% so far this year, meaning that AGTC is slightly underperforming its industry in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on AGTC as it attempts to continue its solid performance.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportApplied Genetic Technologies Corporation (AGTC) : Free Stock Analysis ReportTo read this article on Zacks.com click here.

Visit link:
Is Applied Genetic Technologies (AGTC) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Read More...

Coronavirus: BAME deaths urgently need to be understood, including any potential genetic component – The Conversation UK

Monday, May 25th, 2020

The difference in COVID-19 death rates between white people and black, Asian and minority ethnic (BAME) people in the UK is shocking. One recent report found that, between the beginning of February and the end of April 2020, black people in England were 71% more likely than white people to die from COVID-19. And Asian people were 62% more likely.

This disparity has led to an inquiry by Public Health England and funding for urgent academic research into the issue. We expect many factors to be involved, including the disadvantages that BAME people face due to greater chances of poverty and health issues.

But its important that we examine whether there may also be a genetic component to the problem in order to fully understand whats going on. My colleagues and I are conducting research among frontline healthcare workers to try to see if there are any innate differences in the way different peoples immune systems respond to this specific virus, including genetic differences that may be associated with ethnicity.

Researchers have identified a greater chance of dying from COVID-19 among BAME people in several countries aside from the UK, including Norway and the US. There are many social reasons why ethnic minorities may generally be more vulnerable to disease, including a greater chance of malnutrition, more exposure to pollution due to where they live, or greater likelihood of working in less healthy environments.

Inequality and poverty also play a role in the fact that BAME people are more likely to suffer conditions that we know are linked to a greater chance of dying from COVID-19, such as diabetes and heart disease.

Initial data suggests that BAME healthcare workers are more likely to die from COVID-19 than their white colleagues. British Medical Association research has found that BAME doctors are twice as likely as white doctors to feel pressured into working with inadequate PPE when they are at risk of infection. And they are twice as likely not to feel confident enough to raise concerns about workplace safety.

However, all these established facts alone dont seem to explain why the risks of COVID-19 vary between different ethnic groups and are lowest among white people. This is particularly the case when we compare it with other forms of viral pneumonia that do not lead to such a difference.

The study that found BAME people in England were more likely to die from the disease accounted for differences in some underlying health conditions that are strongly linked to social issues, suggesting these werent the main factor. But the preliminary results from another study suggest ethnic minorities arent more likely to die once other factors linked to deprivation are taken into account.

To clarify this issue, its important to examine whether there may be some genetic component that predisposes ethnic minorities to a higher risk to COVID-19, while still recognising the critical role of other factors.

The way peoples immune systems work depends on genetic factors, not just environmental and social ones. There are effectively two parts to our immune systems. One is the part that produces antibodies, called the adaptive immune system. When our body has never seen a virus before, it can take several days for it to produce them, which is why some people get sick in the first place.

We also have an innate immune system that acts before our body has had time to make antibodies. This system is strong in children and young people, but not very good after the age of 65. This is likely to be one reason why older people are at higher risk of dying of COVID-19.

When a virus like the coronavirus SARS-CoV-2 enters a cell, molecules called toll-like receptors, or TLRs, alert the immune system that something potentially harmful is present. Interestingly, many of the bodys TLRs that can detect viruses come from genetic instructions found in the X chromosome, for which men have only one copy and women two.

We know that women can have a more effective innate immune response to other viruses such as HIV than men, and that oestrogen, the female hormone, enhances this type of immune response. We also know that women are less likely to die from COVID-19 than men.

Just as there are variations in DNA that are responsible for the differences in response of immune cells between the sexes, there can also be variations between people of different ethnic backgrounds. For example, the amount and type of genes that immune cells produce when the TLR-virus pathway is stimulated, are very different between people of African and of European origin.

This is not surprising, because we know that human populations from different parts of the planet have had to adapt to different types of infections. Ethnic differences in the risk to other respiratory viral diseases have been linked to genetic variation, and these variants are different in BAME groups and white people in these same pathways. However, the role of ethnicity in genetic susceptibility to viral diseases is still controversial.

We want to see if it could be a factor in the higher rate of BAME deaths from COVID-19. To do this, we are taking blood from frontline healthcare workers of a variety of ethnic backgrounds, assessing DNA differences and measuring the various substances the samples contain. The results could indicate if differences in the innate immune systems of BAME groups result in higher risk of developing severe COVID-19.

If there is some genetic element to the different death rates from COVID-19 between ethnic groups, its important that we understand it to give us the best chance of fighting the disease. For example, if we do find that the way the innate immune system works plays a role, we can advise people on ways to improve that system, such as through what we eat.

But that wont change the fact that the generally worse health among BAME groups in western societies is strongly linked to socioeconomic factors that are known to play a very significant role in this pandemic.

Read more:
Coronavirus: BAME deaths urgently need to be understood, including any potential genetic component - The Conversation UK

Read More...

Girl, 12, diagnosed with rare genetic condition following visit to Specsavers – Mirror Online

Monday, May 25th, 2020

A 12-year-old girl is on a diet 'stricter than vegan' after a routine eye examination led to her being diagnosed with a rare genetic condition.

Hallie Melling from Old Swan in Liverpool, was initially believed to have been suffering from dyspraxia because she was disorientated and always falling at school.

When school staff advised her 30-year-old mum Amy-Lea to get her eyes tested it lead to a referral to Alder Hey hospital where medics discovered she had Homocystinuria (HCU).

HCU is a metabolic disorder that prevents the normal breakdown of protein and can affect the brain, eyes, skeleton and the vascular system, Liverpool Echo reports.

Amy-Lea said: Since 2015, they have had a heel prick test that babies get to get tested for it, but they didnt have it when Hallie was born.

We're testing a new site:This content is coming soon

Shes had six years of this building up in her system and has had to face the consequences.

When she was in reception school they said she had dyspraxia because she was always falling, not very good at PE and was getting disorientated.

Then that led on to them telling us to get her eyes checked because shes making up what the pictures are in the stories.

So we went to a regular Specsavers appointment and got sent away with a sealed envelope to go to Alder Hey.

The ophthalmologist described the effects the condition has had on Hallies sight as if her eye was a trampoline and the supporting strings had been cut.

Over a year, Hallies sight deteriorated to the point where her glasses prescription was minus 21, and eventually, the lenses in her eyes had to be removed.

After genetic tests, the results came back that Hallie had the rare condition HCU.

According to the NHS, it needs to be treated to avoid serious complications so Hallie will be on medication for the rest of her life and a restricted diet to limit the amount of protein she eats.

Amy-Lea said: The only things she can eat unchecked are fruit and some vegetables.

The rest is prescription food from the chemist and only 18 grams of natural protein a day.

She could go to McDonalds and get a veggie burger meal but that would add up of three-quarters of her daily allowance so we would have to keep her on prescription food for the rest of the day.

She used to be a brilliant eater, she would go to her nans and eat liver and everything.

Now her diet is more strict than a vegan diet.

Amy-Lea said that when Hallie was first diagnosed in 2015 it felt like a life sentence but the way her daughter takes the condition has given her hope.

She said: Within a year of going to Specsavers we were under ophthalmology, genetics and cardiology because it affects your heart.

It also affects her visual memory and she has low bone density.

Were trying to strengthen her bones now because if she doesnt use them they will become very brittle.

When she was doing PE first at school after being diagnosed we were concerned but we were encouraged not to wrap her in cotton wool.

She added: Its all down to Hallie. We were all doom and gloom at first but the way she deals with it makes us deal with it."

Read the rest here:
Girl, 12, diagnosed with rare genetic condition following visit to Specsavers - Mirror Online

Read More...

Close Genetic Relative of SARS-CoV-2 Found in Bats Offers More Evidence It Evolved Naturally – SciTechDaily

Monday, May 25th, 2020

There is ongoing debate among policymakers and the general public about where SARS-CoV-2, the virus that causes COVID-19, came from. While researchers consider bats the most likely natural hosts for SARS-CoV-2, the origins of the virus are still unclear.

Recently, in the journal Current Biology, researchers describe a recently identified bat coronavirus that is SARS-CoV-2s closest relative in some regions of the genome and which contains insertions of amino acids at the junction of the S1 and S2 subunits of the viruss spike protein in a manner similar to SAR-CoV-2. While its not a direct evolutionary precursor of SARS-CoV-2, this new virus, RmYN02, suggests that these types of seemingly unusual insertion events can occur naturally in coronavirus evolution, the researchers say.

Since the discovery of SARS-CoV-2 there have been a number of unfounded suggestions that the virus has a laboratory origin, says senior author Weifeng Shi, director and professor at the Institute of Pathogen Biology at Shandong First Medical University in China. In particular, it has been proposed the S1/S2 insertion is highly unusual and perhaps indicative of laboratory manipulation. Our paper shows very clearly that these events occur naturally in wildlife. This provides strong evidence against SARS-CoV-2 being a laboratory escape.

The researchers identified RmYN02 from an analysis of 227 bat samples collected in Yunnan province, China, between May and October of 2019. Since the discovery that bats were the reservoir of SARS coronavirus in 2005, there has been great interest in bats as reservoir species for infectious diseases, particularly as they carry a very high diversity of RNA viruses, including coronaviruses, Shi says. RNA from the samples was sent for metagenomic next-generation sequencing in early January 2020, soon after the discovery of SARS-CoV-2.

Across the whole genome, the closest relative to SARS-CoV-2 is another virus, called RaTG13, which was previously identified from bats in Yunnan province. But RmYN02, the virus newly discovered here, is even more closely related to SARS-CoV-2 in some parts of the genome, including in the longest encoding section of the genome called 1ab, where they share 97.2% of their RNA. The researchers note that RmYN02 does not closely resemble SAR-CoV-2 in the region of the genome that encodes the key receptor binding domain that binds to the human ACE2 receptor that SARS-CoV-2 uses to infect host cells. This means its not likely to infect human cells.

The key similarity between SARS-CoV-2 and RmYN02, is the finding that RmYN02 also contains amino acid insertions at the point where the two subunits of its spike protein meet. SARS-CoV-2 is characterized by a four-amino-acid insertion at the junction of S1 and S2; this insertion is unique to the virus and has been present in all SARS-CoV-2 sequenced so far. The insertions in RmYN02 are not the same as those in SARS-CoV-2, which indicates that they occurred through independent insertion events. But a similar insertion event happening in a virus identified in bats strongly suggests that these kinds of insertions are of natural origin. Our findings suggest that these insertion events that initially appeared to be very unusual can, in fact, occur naturally in animal betacoronaviruses, Shi says.

Our work sheds more light on the evolutionary ancestry of SARS-CoV-2, he adds. Neither RaTG13 nor RmYN02 is the direct ancestor of SARS-CoV-2, because there is still an evolutionary gap between these viruses. But our study strongly suggests that sampling of more wildlife species will reveal viruses that are even more closely related to SARS-CoV-2 and perhaps even its direct ancestors, which will tell us a great deal about how this virus emerged in humans.

###

Reference: A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2Cleavage Site of the Spike Protein by Hong Zhou, Xing Chen, Tao Hu, Juan Li, Hao Song, Yanran Liu, Peihan Wang, Di Liu, Jing Yang, Edward C. Holmes, Alice C. Hughes, Yuhai Bi and Weifeng Shi, 10 May 2020, Current Biology.DOI: 10.1016/j.cub.2020.05.023

This work was supported by the Academic Promotion Programme of Shandong First Medical University, the Strategic Priority Research Programme of the Chinese Academy of Sciences, the Chinese National Natural Science Foundation, the National Major Project for Control and Prevention of Infectious Disease in China, the High-End Foreign Experts Program of Yunnan Province, the Taishan Scholars Programme of Shandong Province, the NSFC Outstanding Young Scholars, Youth Innovation Promotion Association of CAS, and an ARC Australian Laureate Fellowship.

Current Biology, Zhou et al.: A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1/S2 cleavage site of the spike protein

Read the original post:
Close Genetic Relative of SARS-CoV-2 Found in Bats Offers More Evidence It Evolved Naturally - SciTechDaily

Read More...

How To Interpret Genetic Predisposition For Weight Gain From DNA Kits – Women’s Health

Monday, May 25th, 2020

Adriana Romero-Olivares signed up for 23andMe about seven years ago because she was curious about her ancestry. But the DNA testing company sends updated reports to its customers as it develops them, so in 2018, Adriana received an email notifying her that she had a new report available: a Genetic Weight report. She clicked, and it told her, Adriana, your genes predispose you to weigh about 9 percent more than average.

Learning that info was a strange pill for her to swallow. Ive struggled with my weight my entire life, says Adriana, 35. When I got the results, I felt validated, but then at the same time, I felt upset, because I struggle to accept the fact that I just can't be thin.

Over the past few years, DNA testing companies have started churning out reports like that one that specifically tell someone their likelihood of becoming overweight or obese. The thing is, getting bold text in your inbox that says you have a higher propensity to gain weight than the other people in your HIIT class can feel like a bit of a bomb, as Adriana points out.

So how reliable are these reportsand can they actually aid your efforts if you're trying to lose weight? Heres what experts have to say.

Just from pure observation, you can tell that theres a genetic component because you can look at families and see that weight gain runs in families, says Rachel Mills, a certified genetic counselor and assistant professor in the University of North Carolina-Greensboro Genetic Counseling Program. Beyond that, it gets more complicated.

Researchers dont have a firm answer in terms of to what degree being medically overweight or obese is influenced by genetics, compared to lifestyle and environmental factors. They've estimated that anywhere from 40 to 70 percent of person-to-person variability in body mass index (BMI) is due to genetic factors. (Obvious alert: Thats a wide range.)

And while researchers have already discovered hundreds of genetic variants associated with BMI, weve only got a partial picture of the genetic component so far, says Struan F.A. Grant, PhD, director of the Center for Spatial and Functional Genomics at Childrens Hospital of Philadelphia. Grant notes that BMI is a very polygenic trait, which means there are many, many genetic factors contributing to the trait, he explains. Each genetic variant could have a somewhat different effect on BMI, toothats something experts are still figuring out.

Just because a genetic report says that you are less likely to lose weight, that is not an absolute. Rachel Mills, genetic counselor

So what does it mean if a person has several genetic variants associated with obesity? Once we have a more complete picture of how genes drive obesity risk, we could eventually be able to get data (say, from our doctor) that helps guide how we approach weight management on a personal level, Grant says. But right now, all we definitely know is that certain genetic variants are more common in obese people compared to non-obese people.

23andMes Genetic Weight reports even explain right under your results that your predisposition doesnt mean you definitely will weigh more or less than average. 23andMe senior product scientist Alisa Lehman says that, in 23andMes model, the genetic component [accounts for] less than 10 percent of what the total difference in weight between any two people is. The company does extensive user testing before releasing reports that delve into new areas, she says. And, in this case, they wanted to make sure that customers have an understanding that genes are only one factor in weight management.

How businesses gather weight predisposition info varies company to company. For example, health-focused DNA testing and supplement company Vitagene and weight-loss platform Lose It! use results from other institutions research papers to internally calculate a persons risk of becoming overweight. (Lose It! also asks you to input your AncestryDNA or 23andMe raw DNA filesthe company doesnt do its own DNA testing.)

But 23andMe, arguably the most well-known service, uses its own data to come up with a persons weight predisposition. We have a research program that allows people to answer questions and then, from that, if they opt in, we can use their data to make new genetic discoveries, Lehman explains.

23andMe researchers released the Genetic Weight report in March 2017. They created it by looking at data from more than 600,000 research participants, including their DNA and self-reported height and weight. (Check out a sample report here.)

23andMe researchers found 381 variants associated with BMI, and used that info to create a modeling process that weighs certain variants more strongly than others and considers age, sex, and ancestry to determine the result they send to a consumer. "So when people provide us their saliva sample and we gather their DNA, we can look at those 381 places and say, 'Hey, okay, you have some variants that increase your predisposition and some variants that decrease your predisposition, and the magnitude of each of those variants differ a little bit,'" explains Lehman. "But we add up the effect of all of that to get a sense of whether your predisposition is to [weigh] a little bit more or a little bit less than average."

Depending on your ethnicity, there might also be another caveat. The largest population that 23andMe has data for is people of European descent, so researchers were only able to look at genetic and BMI data from people of European descent to identify the weight-related genetic variants and their effects. Then they looked at how well that model worked for people of other ethnicities, tweaking the model as necessary. Therefore, people who have Latino, African American, East Asian, and South Asian ancestry can get results that are somewhat customized to their ancestry, while people of mixed ancestry or other ancestries default to European. (This Eurocentric bias comes up in a *lot* of research that scans peoples genomes for genetic variants associated with a disease or trait, not just in relation to BMI.)

It doesnt appear that any companies that provide weight-related DNA results have conducted any formal research on how the info impacts peoples weight-loss efforts. Lehman says 23andMe has looked a little bit into whether the information in the Genetic Weight report has actually helped consumers with weight loss or management, but that they havent come up with anything "publication-worthy," adding that its challenging to untangle this report from other info the company provides on nutrition and exercise.

23andMe also hasnt taken a fresh look at their Genetic Weight report model since releasing it, but it plans to. We do periodically review all of the reports that we have, and Genetic Weight is coming up for that periodic review, so we will soon review it and see if any updates are warranted, Lehman says.

23andMes Health + Ancestry Service

This product includes a Genetic Weight report that tells you how much more or less than average your genes predispose you to weigh. It also explains that your predisposition doesnt mean you definitely will weigh more or less than average. Keep in mind that your lifestyle and environment have a big impact on your weight, the report reads.

HomeDNA Healthy Weight

This report tells you your general weight loss ability with diet and exercise. On a page explaining those results, the report reads: "Remember that these results only indicate your potential based on genetic factors, but many other factors also affect the outcome."

Lose It! Premium

Once you upload your AncestryDNA or 23andMe raw DNA file, this platform will tell you whether or not you have a genetic risk of being overweight or obese. In a disclaimer, the report says, These genetic variants are not perfectly predictive. You may have a high genetic score and a low BMI, or a low genetic score and a high BMI. These results may be more accurate for people of certain ethnic backgrounds.

Vitagenes Health + Ancestry DNA Tests and Reports

Customers can learn whether their genetics may make them more or less likely to become overweight with this kit. The info includes this caveat: However, your genetics alone dont define your body weight. Making healthy lifestyle choices may help keep you from becoming overweight. (Customers also have the option to upload their own raw DNA results for $29.)

Of course, some people might just like or even be motivated by having more information about themselves, and thats totally fair. But heres an interesting twist: A recent study out of Stanford University found that just knowing your genetic risk for obesity can impact the way you respond to food.

In one of two experiments, participants ate a meal and then, on a different day, ate another after hearing that they did or didn't have a high-risk genetic variant associated with obesity and lower satiety. Heres the catch: Researchers chose randomly whether participants would be told they had the genetic variant. (The researchers fully debriefed the participants about their actual genetic risk only about an hour later, while they were still under clinical supervision.)

We saw that the information we gave to people was like a self-fulfilling prophecy, says Brad Turnwald, PhD, a postdoctoral research fellow in the department of psychology at Stanford University and lead author of the study. When researchers told people they didnt have an increased risk, they reported feeling full faster and even produced more of a fullness hormone. Overall, what we saw was that what people thought had as much of an impact, and in some cases a greater impact, than what peoples actual gene sequence was, Turnwald says.

The takeaway, says Turnwald, is that we need to better understand the psychological impact of these kinds of DNA test products. We're definitely not trying to say that genes don't matter at all. There are some diseases for which they really are predictive, he says. But for the majority of things like weight loss and how hungry we are and how well we exercisethings for which people are looking for explanations that they just weren't made to run or they just don't feel full based on their genesthe story is not going to be that simple.

Mills doesnt believe that its possible for any sort of calculation to exist at the moment that can accurately analyze a persons propensity to gain weight. If someone told her they were interested in one of these reports, she would ask them to think seriously about how you would use that information, Mills says.

I know, for me personally, I would see a report [that says I cant lose weight as well through diet and exercise] and maybe throw up my hands and be like, Well, Im just going to go to McDonalds because it doesn't matterno diet and exercise is ever going to help me lose weight, so why do I need to even try she continues. And that can have a really detrimental effect.

If someone has already received genetic weight report results and asked her how to interpret themor wants to know how damning they actually are, so to speakMills would emphasize this: Genetics is just one piece of the big picture, she says. Just because this genetic report says that you are less likely to lose weight, that is not an absolute.

Adriana is Mexican, and shes also a scientist, so she knows that she should take her reported propensity to be overweight with a grain of salt. She says her Genetic Weight report is one piece of information, an indicator that I tend maybe to gain weight or that my metabolism is not as fast as the average persons, she says. But shes not going to make major lifestyle changes based on it.

Over time, though, the report has had a positive effect on Adrianas mindset: The way that I think about it now is, if Im predisposed to weigh a little bit more than the average person, then I might as well just exercise and have a balanced diet for the sake of health and not necessarily for the sake of losing weight, which, for a very long time, was the main focus for me.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

See more here:
How To Interpret Genetic Predisposition For Weight Gain From DNA Kits - Women's Health

Read More...

Global Impact of Covid-19 on Animal Genetic Products Market Insights 2020 Industry Overview, Competitive Players & Forecast 2027 | Genus Plc,…

Monday, May 25th, 2020

The research report on Animal Genetic Products market Added by Reports And Data, proposes a comprehensive study on the recent industry trends. In addition, the report presents a detailed abstract of the growth statistics, revenue estimation, and market valuation, and also highlights the state of the competitive spectrum and expansion strategies adopted by major industry players. players like (Genus Plc, Hendrix Genetics BV, Alta Genetics, CRV Holdings B.V., Neogen Corporation, VatGen, Animal Genetics Inc., Zoetis, Urus, and Envigo among)

The research report on Animal Genetic Products market exhaustively analyzes this business space with focus on overall renumeration over the assessment period, alongside the detailed scrutiny of various industry segments. The report entails information pertaining to the current position and industry size based on volume. The overview of various drivers, restraints, and opportunities defining the business scenario of Animal Genetic Products market is presented in the study. It also focuses on insights about the regional outlook of the market, coupled with an elaborate study of companies with prominent stake in the

Download Free sample report at: https://www.reportsanddata.com/sample-enquiry-form/1344

The study reveals that the global Animal Genetic Products market is projected to reach a market value of USD 7.13 Billion by the end of 2027 and grow at a CAGR of 6.3% during the assessment period. Further, a qualitative and quantitative analysis of the Animal Genetic Products market based on data collected from various credible sources in the market value chain is included in the report along with relevant tables, graphs, and figures.

What questions does the Animal Genetic Products market report answer pertaining to the regional reach of the industry?

Access Full Research Report at: https://www.reportsanddata.com/report-detail/animal-genetic-products-market

Segments covered in the report:

Live Animals Outlook (Revenue, USD Billion; 2018-2026)

Genetic Material Outlook (Revenue, USD Billion; 2018-2026)

Testing Services Outlook (Revenue, USD Billion; 2018-2026)

The Animal Genetic Products market report highlights the regions, particularly inNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

A short overview of the Animal Genetic Products market scope:

Reasons to Read this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Oder now: https://www.reportsanddata.com/checkout-form/1344

Some of the Major Highlights of TOC covers:

Chapter 1. Market Synopsis

1.1. Market Definition

1.2. Research Scope & Premise

1.3. Methodology

1.4. Market Estimation Technique

Chapter 2. Executive Summary

2.1. Summary Snapshot, 2017 2027

Chapter 3. Indicative Metrics

3.1. Macro Indicators

Chapter 4. Animal Genetic Products Market Segmentation & Impact Analysis

4.1. Animal Genetic Products Segmentation Analysis

4.2. Industrial Outlook

4.3. Price Trend Analysis

4.4. Regulatory Framework

4.5. Porters Five Forces Analysis

4.5.1. Power Of Suppliers

4.5.2. Power Of Buyers

4.5.3. Threat Of Substitutes

4.5.4. Threat Of New Entrants

4.5.5. Competitive Rivalry

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics and industries to help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure that our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John Watson

Head of Business Development

Reports And Data | Web: http://www.reportsanddata.com

Direct Line: +1-800-819-3052

E-mail: [emailprotected]

Read more:
Global Impact of Covid-19 on Animal Genetic Products Market Insights 2020 Industry Overview, Competitive Players & Forecast 2027 | Genus Plc,...

Read More...

Enhancing food diversity in the midst of a climate crisis: How plant genetic material ensures future food security – Kenya – ReliefWeb

Monday, May 25th, 2020

Throughout history 6 000 -- 7 000 plant species have been cultivated for food. Yet today 40 percent of our daily calories come from just three crops: rice, wheat and maize. Humans depend on little more than 30 plant species, many of which are struggling in the face of today's environmental changes. With biodiversity and entire ecosystems in serious decline, the International Treaty on Plant Genetic Resources for Food and Agriculture plays an increasingly important role in promoting farmers and their essential contribution to diversifying the crops that feed the world. The Treaty was negotiated by FAO and the Commission on Genetic Resources for Food and Agriculture (CGRFA) and adopted in 2001 to create a global system that provides farmers, plant breeders and scientists with access to plant genetic materials.

The genetic material in each variety of species is unique and precious. Derived from human and natural selection for many decades, these genetics are fundamental to our future of food. Genetic material ensures agricultural biodiversity and gives different species the ability to cope with changes, whether it be climate change, new pests and diseases, drought and even flooding. The Treaty's Benefit-sharing Fund invests in projects that conserve and develop crop genetic resources to improve food security in cooperation with farmers.

Here are three examples of how this Treaty has helped farming communities in developing countries cope with climate change and other environmental threats.

1. Exchanging and developing biodiverse potato varieties in Peru, Nepal and Bhutan

There are over 4 000 native varieties of potato growing in the Andean highlands. These varieties are well-adapted to harsh conditions and a changing climate. In contrast, Nepal and Bhutan have only two locally adapted potato varieties but face similar conditions and environmental threats as the Andes. With this in mind, the project sought to reduce the vulnerability of these mountain communities by introducing potatoes that are more resilient to extreme temperatures and offer better nutritional quality. Working closely with the International Potato Centre in Peru, farmers in Nepal and Bhutan became directly involved in selecting new, high-yielding, resilient and biodiverse varieties of potato. The genetic material from these potatoes has since been conserved, multiplied and used by national agricultural research systems in all three countries.

** 2. Conserving plant genetic resources to improve food and nutrition in Zimbabwe, Malawi and Zambia

Being heavily reliant on the success of the maize crop, communities in Zimbabwe, Malawi and Zambia have in recent years faced a severe food shortage because maize crops have been unable to withstand the effects of climate change, such as higher temperatures and torrential rains. "Because of the changing climate, our farm was producing less food, and most crops have not been doing so well apart from millet and sorghum," explained Lovemore Tachokere, a smallholder farmer from Malawi. Through the Benefit-sharing fund and the introduction of 159 Farmer Field Schools across the three countries, farmers were given support and a voice. They started introducinglost varieties of different crops, creating diversity in their fields that also ensured more varied and nutritious diets. As part of the project a total of 300 lost or forgotten small grain crop varieties were retrieved from national, regional and international gene banks as part of the Treaty's Multilateral System. These seeds are now available to farmers and scientists for further study and the development of new climate-smart varieties.

3. Ensuring a resilient cassava crop in Tanzania and Kenya

Cassava is the third largest source of carbohydrates in the world, playing a particularly important role in agriculture in sub-Saharan Africa because it does well in poor soils and with low rainfall. Additionally, because it is a perennial, cassava acts as a famine reserve. In recent years, however, extreme temperatures, drought, flooding and a new virus, provoking 'brown streak disease', have affected cassava cultivation in the region. In Tanzaniaand Kenya, a project implemented through the Benefit-sharing Fund has led to new, more resistant and tolerant cassava breeding lines, including 30 that are heat and disease tolerant. While the farmers are now experimenting with planting new cassava varieties and using improved agricultural practices, breeders and scientists have access to improved plant material from which to select essential genetic material for future use. Community seed banks have been established through the Benefit-sharing Fund in conjunction with Farmer Field Schools and are an important initiative to collect and conserve local crop varieties. They function as a platform for farmers to control and make informed decisions on the conservation of agrobiodiversity and the cultivation of a variety of crops with nutritional value.

In the 15 years since it came into force, the International Treaty hosted by FAO has created the largest global gene pool for sharing plant material for food and agriculture, the Multilateral System of Access and Benefit-sharing (MLS). The Benefit-sharing Fund has supported over one million people through 80 agricultural development projects in 67 developing countries. These projects are clear examples of how effective the sharing of skills and knowledge across continents can be and they are crucial in the race to meet the Sustainable Development Goals (SDGs), in particular SDG 15 (Life on Land) and SDG2 (Zero Hunger). Projects under the Benefit-sharing Fund are an indication that FAO's Strategy on mainstreaming biodiversity across agricultural sectors is already taking shape and showing positive results, demonstrating that the greater the diversification of crops, the more food secure a community can become and the more resilient they find themselves in the face of current threats like climate change, pests and disease.

Go here to read the rest:
Enhancing food diversity in the midst of a climate crisis: How plant genetic material ensures future food security - Kenya - ReliefWeb

Read More...

Colonizing Mars may require humanity to tweak its DNA – Livescience.com

Monday, May 25th, 2020

If humanity is ever going to settle down on Mars, we may need to become a little less human.

Crewed missions to Mars, which NASA wants to start flying in the 2030s, will be tough on astronauts, exposing them to high radiation loads, bone-wasting microgravity and other hazards for several years at a time. But these pioneers should still be able to make it back to Earth in relatively good nick, agency officials have said.

It might be a different story for those who choose not to come home, however. If we want to stay safe and healthy while living permanently on Mars, or any other world beyond our home planet, we may need to make some tweaks to our species' basic blueprint, experts say.

Related: Space radiation threat to astronauts explained (infographic)

Genetic engineering and other advanced technologies "may need to come into play if people want to live and work and thrive, and establish their family, and stay on Mars," Kennda Lynch, an astrobiologist and geomicrobiologist at the Lunar and Planetary Institute in Houston, said on May 12 during a webinar hosted by the New York Academy of Sciences called "Alienating Mars: Challenges of Space Colonization."

"That's when these kinds of technologies might be critical or necessary," she said.

Genetic enhancement may not be restricted to the pages of sci-fi novels for much longer. For example, scientists have already inserted genes from tardigrades tiny, adorable and famously tough animals that can survive the vacuum of space into human cells in the laboratory. The engineered cells exhibited a greater resistance to radiation than their normal counterparts, said fellow webinar participant Christopher Mason, a geneticist at Weill Cornell Medicine, the medical school of Cornell University in New York City.

NASA and other space agencies already take measures to protect their astronauts physically, via spacecraft shielding, and pharmacologically via a variety of medicines. So, it's not a huge conceptual leap to consider protecting them genetically as well, provided that these measures are proven to be safe, Mason said.

"And are we maybe ethically bound to do so?" he said during the webinar. "I think if it's a long enough mission, you might have to do something, assuming it's safe, which we can't say yet."

Tardigrades and "extremophile" microbes, such as the radiation-resistant bacterium Deinococcus radiodurans, "are a great, basically natural reservoir of amazing traits and talents in biology," added Mason, who has been studying the effects of long-term spaceflight on NASA astronaut Scott Kelly. (Kelly spent nearly a year aboard the International Space Station in 2015 and 2016.) "Maybe we use some of them."

Harnessing these traits might also someday allow astronauts to journey farther than Mars, out to some even more exotic and dangerous cosmic locales. For instance, a crewed journey to the Jupiter moon Europa, which harbors a huge ocean beneath its icy shell, is out of the question at the moment. In addition to being very cold, Europa lies in the heart of Jupiter's powerful radiation belts.

"If we ever get there, those are the cases where the human body would be almost completely fried by the amount of radiation," Mason said. "There, it would be certain death unless you did something, including every kind of shielding you could possibly provide."

Genetic engineering at least lets us consider the possibility of sending astronauts to Europa, which is widely regarded as one of the solar system's best bets to harbor alien life. (The Jovian satellite is a high priority for NASA's robotic program of planetary exploration. In the mid-2020s, the agency will launch a mission called Europa Clipper, which will assess the moon's habitability during dozens of flybys. And Congress has ordered NASA to develop a robotic Europa lander as well, though this remains a concept mission at the moment.)

Related: The 6 most likely places to find alien life

Genetic engineering almost certainly won't be restricted to pioneering astronauts and colonists. Recent advances in synthetic biology herald a future in which "designer microbes" help colonists establish a foothold on the Red Planet, Lynch said.

"These are some of the things that we can actually do to help us make things we need, help us make materials to build our habitats," she said. "And these are a lot of things that scientists are researching right now to create these kinds of things for our trip to Mars."

Some researchers and exploration advocates have even suggested using designer microbes to terraform Mars, turning it into a world much more comfortable for humans. This possibility obviously raises big ethical questions, especially considering that Mars may have hosted life in the ancient past and might still host it today, in subsurface lakes or aquifers. (Permanently changing our own genomes for radiation protection or any other reason may also strike some folks as ethically dubious, of course.)

Most astrobiologists argue against terraforming Mars, stressing that we don't want to snuff out or fundamentally alter a native ecosystem that may have arisen on the Red Planet. That would be both unethical and unscientific, Lynch said.

After all, she said, one of the main reasons we're exploring Mars is to determine if Earth is the only world to host life.

"And how can we do that if we go and change the planet before we go and find out if life actually was living there?" Lynch said.

Mike Wall is the author of "Out There" (Grand Central Publishing, 2018; illustrated by Karl Tate), a book about the search for alien life. Follow him on Twitter @michaeldwall. Follow us on Twitter @Spacedotcom or Facebook.

View original post here:
Colonizing Mars may require humanity to tweak its DNA - Livescience.com

Read More...

What Is The Connection Between Diabetes And Thirst? – South Florida Reporter

Sunday, May 24th, 2020

What is excessive thirst?

Age, lifestyle, and activity levels can contribute to how much a person drinks.

According to theCenters for Disease Control and Prevention (CDC), there are currently no guidelines about how much water a person should drink each day.

In 2004, theInstitute of Medicineestimated an adequate daily water intake as 3.7 liters for males and 2.7 liters for females. These amounts included water from all the drinks and foods in a persons diet.

According to theNational Health and Nutrition Examination Survey, 20092012, males in the United States tend to consume 3.46 liters of water per day, while females in the country typically consume 2.74 liters per day. These figures also included water from all dietary sources.

However, from day to day, a person may feel more or less thirsty for a variety of reasons. Spending time in the sun or being especially active, for example, can contribute to thirst.

Diabetes that causes excessive thirst

Different types of diabetes can cause excessive thirst.

The term diabetes mellitusincludesdiabetes types 1 and 2.

A person withtype 1 diabetesis unable to produceinsulin.

Someone withtype 2 diabetesis able to produce insulin, but their body is unable to use it effectively to help glucose enter cells.

In either case, glucose from digested food remains in the bloodstream.

As the authors of a2014 articlenote, the kidneys excrete some excess glucose through urine. As the glucose draws water into the urine, the body loses more fluid than it should. This results in the person becoming extra thirsty.

Gestational diabetesoccurs during pregnancy.

Just as in a person with diabetes mellitus, in a woman with gestational diabetes,insulin resistancecanlead tohyperglycemia.

For the reasons that we describe in the section above, this can lead to an increased need to urinate and excessive thirst.

Diabetes insipidusis arare conditionthat involves the kidneys passing an unusually high amount of urine, which is diluted and odorless.

Typically, the kidneys pass about12 quartsof urine a day. In someone with diabetes insipidus, the kidneys can pass320 quartsa day. This results in the person being excessively thirsty.

Unlike a person with diabetes mellitus, someone with diabetes insipidus hasnormalblood glucose levels. However, their kidneys are unable to balance the amount of fluid in the body.

This can happen for a number of reasons, including:

The factors above can disrupt the function of the hormone vasopressin. This hormone works with the brain and kidneys to help regulate fluids in the body.

Original post:
What Is The Connection Between Diabetes And Thirst? - South Florida Reporter

Read More...

Page 16«..10..15161718..3040..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick